Corvus Pharmaceuticals (CRVS) Equity Ratio (2015 - 2026)

Corvus Pharmaceuticals' Equity Ratio history runs 12 years deep, the most recent figure standing at 0.95 for Q1 2026.

• In Q1 2026, Equity Ratio rose 14.55% year-over-year to 0.95; the TTM figure through Mar 2026 stood at 0.95 (up 14.55% YoY), while the FY2025 annual figure was 0.86, up 82.08% from the prior year.
• Equity Ratio was 0.95 for Q1 2026 at Corvus Pharmaceuticals, up from 0.86 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.95 in Q1 2026 to a low of 0.21 in Q3 2024.
• Historically, Equity Ratio has averaged 0.79 across 5 years, with a median of 0.85 in 2023.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio tumbled 75.26% in 2024, then soared 322.69% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.82 in 2022, then rose by 3.27% to 0.85 in 2023, then plunged by 44.34% to 0.47 in 2024, then jumped by 82.08% to 0.86 in 2025, then climbed by 10.45% to 0.95 in 2026.
• The last three Equity Ratio figures came in at 0.95 (Q1 2026), 0.86 (Q4 2025), and 0.89 (Q3 2025), per Business Quant data.